Company Profile: Somnomed Limited (ASX: SOM), provides products and services for the treatment of sleep related breathing disorders including Obstructive Sleep Apnea (OSA) and other breathing disorders. It primarily operates in the Asia Pacific region, North America and Europe. The products range from SomnoDent Fusion, SomnoDent Flex, SomnoDent Classic, and SomnoDent AIR & AIR+ and Morning Repositioner. Additionally, Somnomed provides medical reimbursement services to help dental offices with submitting a medical claim for patients.
Start discussion with value Investors for ASX Stock Market Investment and Opinion.
Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s
Those phrases have become increasingly common as marijuana legalization spreads.
Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500. Click here for your FREE Report